Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide
Diabetes/Metabolism Research and Reviews · 2026
DOI: 10.1002/dmrr.70213 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Ebaa Al Ozairi und 5 weiteren Autor:innen. Beteiligte Einrichtung: DAFNE Unit, Clinical Care Research and Trials Unit, Dasman Diabetes Institute, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Weight Loss, Body Composition, Diabetes Mellitus, Type 1, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kuwait Foundation for the Advancement of Sciences, Ministry of Health Kuwait.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA). Materials and Methods This real‐world observational study included 70 people with obesity and T1D treated with GLP‐1RA alone or dual GIP/GLP‐1RA. Dual‐energy X‐ray absorptiometry (DEXA) was used to quantify regional and total fat mass, lean mass, bone mineral content (BMC) and BMD at baseline and after 12 months of treatment. Overall changes were quantified, and changes stratified by percentage weight loss using repeated measures analysis.
Results
Over 12 months body weight (−6.33%; 95% CI: −7.92, −4.73; p < 0.001), HbA1c (−0.48%; 95% CI: −0.74, −0.22; p < 0.001), total tissue fat (−1.42%; 95% CI: −2.47, −0.36; p = 0.009), fat mass (−5.90%; 95% CI: −10.50, −1.57; p = 0.001), and lean mass (−1.75%; 95% CI: −3.50, −0.48; p = 0.005) decreased, while total BMC and BMD remained unchanged. Total lean mass loss was associated with body weight loss ( R 2 = 0.36, p < 0.001).
Conclusions
In people with obesity and T1D, 12‐month GLP‐1RA alone or dual GIP/GLP‐1RA therapy resulted in clinically meaningful weight loss, improved glycaemic control, preferential fat mass reduction, modest lean mass loss, and preservation of total BMD. People achieving > 10% weight loss derived the greatest metabolic benefit without compromising bone health, although the loss of lean mass was greater.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DAFNE Unit, Clinical Care Research and Trials Unit, Dasman Diabetes Institute, Kuwait City, Kuwait.
- Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait.
- Diagnostic Imaging Center, Dasman Diabetes Institute, Kuwait City, Kuwait.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Diabetes Complications Research Centre, University College Dublin, Dublin, UK.
- School of Medicine, Ulster University, Coleraine, UK.
ORCID-Profile: Ebaa Al Ozairi, Mohammad Irshad, Anant Mashankar, Stuart R Gray, Carel W le Roux
Förderung
- Kuwait Foundation for the Advancement of Sciences
- Ministry of Health Kuwait
Zitieren
APA
Al Ozairi, E., Irshad, M., Alkandri, J., Mashankar, A., Gray, S. R., & le Roux, C. W. (2026). Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70213
Vancouver
Al Ozairi E, Irshad M, Alkandri J, Mashankar A, Gray SR, le Roux CW. Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70213
BibTeX
@article{AlOzairi2026,
author = {Al Ozairi, Ebaa and Irshad, Mohammad and Alkandri, Jumana and Mashankar, Anant and Gray, Stuart R and le Roux, Carel W},
title = {Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
doi = {10.1002/dmrr.70213}
}
EUVIMED